1.73
-0.02 (-1.14%)
| Penutupan Terdahulu | 1.75 |
| Buka | 1.76 |
| Jumlah Dagangan | 420,053 |
| Purata Dagangan (3B) | 791,442 |
| Modal Pasaran | 139,128,656 |
| Harga / Pendapatan (P/E TTM) | 21.63 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.83 |
| Harga / Jualan (P/S) | 2.36 |
| Harga / Buku (P/B) | 2.61 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Keuntungan | 6.54% |
| Margin Operasi (TTM) | -40.99% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 169.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.58% |
| Nisbah Semasa (MRQ) | 2.49 |
| Aliran Tunai Operasi (OCF TTM) | 8.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.29 M |
| Pulangan Atas Aset (ROA TTM) | 3.53% |
| Pulangan Atas Ekuiti (ROE TTM) | 10.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Protalix BioTherapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.63 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 10.39% |
| % Dimiliki oleh Institusi | 10.22% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Opaleye Management Inc. | 30 Sep 2025 | 2,580,556 |
| Diametric Capital, Lp | 30 Sep 2025 | 179,984 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |